CryoStasis closes $8 million seed financing to develop next generation sub-zero unfrozen biopreservation for organ transplantation and cell/gene therapy products

CryoStasis, a company that brings a combination of chemistry, biochemistry and cooling processes to provide cell preservation that has been proven in nature, recently announced that it has secured Seed financing to pursue its plan to develop next generation sub-zero unfrozen cryopreservation solutions. The company’s first financing round was led by Genesys Capital with significant participation from individual investors and the management team.

Cryostasis is an OBIO® member.